Pharmacotherapeutic Group: Antivirals. ATC Code: JO5AX.
Pharmacology: Pharmacodynamics: The medicine exerts antiviral effects upon prophylactic and therapeutic administration. Effectiveness is established experimentally and clinically towards influenza viruses, parainfluenza viruses, herpes simplex virus of type 1 and 2 (labial herpes, genital herpes), other herpes virus diseases (varicella, infectious mononucleosis), enterovirus, tick-borne encephalitis virus, rotavirus, coronavirus, calicivirus, adenovirus, respiratory syncytial virus. The drug reduces the concentration of virus in the affected tissues, influences on the system of endogenous interferons and related cytokines, induces the production of endogenous "early" interferons (IFN a/(3) and interferon gamma (IFN y).
The drug stimulates humoral and cell-mediated immune responses. Affinity-purified antibodies to human interferon gamma (Anaferon) increases antibody production (including secretory IgA), activates the functions of T-effectors and T-helpers (Th) and normalizes their ratio. The drug increases the functional reserves of Th and other cells involved in the immune response. The drug induces combined Th1 and Th2-type immune response through enhancing the production of Thl (IFN y, IL-2) and Th2 (IL-4, 10) cytokines, normalizes (modulates) the Thl/Th2 activity balance. The drug increases the functional activity of phagocytes and natural killer cells (NK cells).
Pharmacokinetics: The sensitivity of contemporary physicochemical methods (gas-liquid chromatography, high performance liquid chromatography and mass spectrometry) does not allow assessing the content of active components of the drug in biological fluids, organs and tissues, that makes technically impossible to investigate the pharmacokinetic properties of Affinity-purified antibodies to human interferon gamma (Anaferon).